Short Term Intermittent Fasting and Insulin Resistance (IFAST)
Primary Purpose
Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
Status
Unknown status
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Intermittent fasting
Time control
Sponsored by
About this trial
This is an interventional treatment trial for Diabetes Mellitus focused on measuring intermittent fasting, alternate day fasting, diabetes mellitus, non-alcoholic fatty liver disease, insulin sensitivity
Eligibility Criteria
Inclusion Criteria:
- BMI 28-35
- Type 2 diabetes or metabolically healthy
- Diet or orally administered treatment for type 2 diabetes
Exclusion Criteria:
- Regular physical activity
- Other diseases than type 2 diabetes
- insulin treatment
- alcohol abuse
Sites / Locations
- Xlab, Department of Biomedical Sciences, University of Copenhagen
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Intermittent fasting
Time control
Arm Description
Intermittent fasting conducted by a group of subjects with type 2 diabetes mellitus and an age- and BMI matched control group.
A time control period.
Outcomes
Primary Outcome Measures
Change from Baseline in Insulin Sensitivity after 20 days of intermittent fasting.
An euglycemic hyperinsulinemic clamp is performed at day 1 and repeated at day 23 after a control period with no change in the diet. Baseline insulin sensitivity is determined based on these two measurements. The euglycemic hyperinsulinemic clamp is repeated at day 46 after the intermittent fasting period (day 25-44) and two days (day 24 and 45) with a normal diet.
Change of insulin secretion
IVGTT performed at baseline, after intermittent fasting without weight loss and again after intermittent fasting with weight loss
Secondary Outcome Measures
Glycogen Content in Skeletal Muscle after a Day of Eating and after a Day of Fasting
Analysis of glycogen content from muscle biopsies obtained after a day of fasting and after a day of eating during the intermittent fasting period.
Change from Baseline in Fat Content in the Liver and Visceral Fat after 20 Days of Intermittent Fasting
Fat content measured by magnetic resonance spectroscopy.
Insulin signalling cascade proteins
By Western blot determine any change in proteins relevant for insulin signalling and turnover of intramyocellular lipids.
Full Information
NCT ID
NCT02420054
First Posted
April 10, 2015
Last Updated
February 8, 2021
Sponsor
University of Copenhagen
Collaborators
Herlev Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02420054
Brief Title
Short Term Intermittent Fasting and Insulin Resistance
Acronym
IFAST
Official Title
Effects of Short Term Intermittent Fasting on Insulin Resistance in Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
April 2015 (Actual)
Primary Completion Date
April 2021 (Anticipated)
Study Completion Date
June 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Copenhagen
Collaborators
Herlev Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to determine the effect of intermittent fasting on insulin secretion and insulin sensitivity in skeletal muscle and fat distribution.
Detailed Description
Approximately 250.000 patients are diagnosed with type 2 diabetes (T2DM) in Denmark, and world-wide close to 350 million people suffer from diabetes. T2DM develops in genetically susceptible individuals as a result of excess energy intake and insufficient amount of daily physical activity. The pathophysiology encompasses a mismatch between the insulin secretory capacity and insulin sensitivity, predominantly manifested in skeletal muscle as insulin resistance. T2DM is associated with increased morbidity and mortality.
The disease is triggered by the individual lifestyle, and thereby the potential for prevention and reversal of the disease in its early years after diagnosis is quite large.
One potential way to improve glucose homeostasis is by intermittent fasting, also known as alternate day fasting. Intermittent fasting means switching between eating and fasting, and it is a variation of calorie restriction. Intermittent fasting has been studied in animals. Together with calorie restriction, intermittent fasting is the most efficient way to expand lifespan of many animal species without genetically altering them. A wide range of age related changes are delayed including beneficial effects on hypertension, degenerative brain disease, immune responses, DNA repair capacity and glucose homeostasis. Fat redistribution with fat translocating from between the organs and the liver to the subcutis.
Little is known about intermittent fasting in humans. In 2005 the investigators experimentally tested this concept in young healthy males and found that 15 days of alternating days with fast and food intake increased insulin sensitivity by 16% without any changes in body weight.
The explanation could be oscillations in cellular energy stores. Skeletal muscle contains approximately 80% of the stored glycogen alone by virtue of the muscle mass. The liver has a higher glycogen concentration, but it is much smaller. A single prolonged (>24 hrs) day of fasting may not decrease muscle glycogen, while the decrease in the liver is very fast. A muscle glycogen lowering effect of continued intermittent fasting would be expected, and experimentally indicated.
The intermittent fasting method may appeal to some patients, who do not exercise, and the need for testing this intervention in patients with type 2 diabetes is obvious.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome, Obesity
Keywords
intermittent fasting, alternate day fasting, diabetes mellitus, non-alcoholic fatty liver disease, insulin sensitivity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intermittent fasting
Arm Type
Active Comparator
Arm Description
Intermittent fasting conducted by a group of subjects with type 2 diabetes mellitus and an age- and BMI matched control group.
Arm Title
Time control
Arm Type
Active Comparator
Arm Description
A time control period.
Intervention Type
Behavioral
Intervention Name(s)
Intermittent fasting
Intervention Description
Alternate day fasting (ADF) (water permitted) for 3 weeks with double energy intake every other day. Followed by ADF for 3 weeks with ad libitum diet on eating days.
Intervention Type
Other
Intervention Name(s)
Time control
Intervention Description
Time control period with no change in eating habits.
Primary Outcome Measure Information:
Title
Change from Baseline in Insulin Sensitivity after 20 days of intermittent fasting.
Description
An euglycemic hyperinsulinemic clamp is performed at day 1 and repeated at day 23 after a control period with no change in the diet. Baseline insulin sensitivity is determined based on these two measurements. The euglycemic hyperinsulinemic clamp is repeated at day 46 after the intermittent fasting period (day 25-44) and two days (day 24 and 45) with a normal diet.
Time Frame
46 days
Title
Change of insulin secretion
Description
IVGTT performed at baseline, after intermittent fasting without weight loss and again after intermittent fasting with weight loss
Time Frame
46 days
Secondary Outcome Measure Information:
Title
Glycogen Content in Skeletal Muscle after a Day of Eating and after a Day of Fasting
Description
Analysis of glycogen content from muscle biopsies obtained after a day of fasting and after a day of eating during the intermittent fasting period.
Time Frame
46 days
Title
Change from Baseline in Fat Content in the Liver and Visceral Fat after 20 Days of Intermittent Fasting
Description
Fat content measured by magnetic resonance spectroscopy.
Time Frame
23 days
Title
Insulin signalling cascade proteins
Description
By Western blot determine any change in proteins relevant for insulin signalling and turnover of intramyocellular lipids.
Time Frame
46 days
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
BMI 28-35
Type 2 diabetes or metabolically healthy
Diet or orally administered treatment for type 2 diabetes
Exclusion Criteria:
Regular physical activity
Other diseases than type 2 diabetes
insulin treatment
alcohol abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Flemming Dela, MD, DMSc
Organizational Affiliation
University of Copenhagen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Xlab, Department of Biomedical Sciences, University of Copenhagen
City
Copenhagen
ZIP/Postal Code
2200
Country
Denmark
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Short Term Intermittent Fasting and Insulin Resistance
We'll reach out to this number within 24 hrs